Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.
For the past several decades, HIV and AIDS have dominated discussions and reporting about LGBT health. While HIV/AIDS continues to be relevant to this population, thorough coverage of health for lesbian, gay, bisexual and transgender individuals must be much more comprehensive in examining other challenges they face.
Several takeaways from the Health Journalism 2016 session, “Beyond HIV/AIDS: Reporting on the LGBT Community,” can help reporters go beyond those issues to discover new stories and important trends. Two major themes emerged from the session that offer fertile ground for deeper reporting. Continue reading →
Eileen Beal, M.A., has been covering health care and aging since the late 1990s. She's written several health-related books. including "Age Well!" with geriatrician Robert Palmer, and her work has appeared in Aging Today, Arthritis Today,WebMD and other publications.
Over the past two years, patient advocacy groups, researchers and consultants have said health insurers have discriminated against their members with high-cost conditions.
A number of journalists have covered these stories. The Marketplace’s Tim Fitzsimons reported in June that the federal Department of Health and Human Services was addressing complaints against insurers whose benefit programs were designed to drive away members with costly pre-existing conditions. Wes Venteicher of the Chicago Tribunereported on efforts by health insurer Coventry to make HIV treatments more affordable after patient advocates complained that costs for HIV drugs were too high. Continue reading →
Anna Gorman (@AnnaGorman) is a senior correspondent with Kaiser Health News. She attended Health Journalism 2015 on an AHCJ-California Health Journalism Fellowship, which is supported by The California HealthCare Foundation.
Pia Christensen/AHCJSharon Hillier, a professor at the University of Pittsburgh School of Medicine, discusses the pre-exposure prophylaxis pill, or PrEP, which can help prevent HIV infection.
HIV prevention and treatment have undergone a revolution since the disease first appeared, but there are still barriers to reaching the most at-risk populations, HIV experts said during a session at Health Journalism 2015.
While HIV patients in 1985 had a life expectancy of at most 10 years, now they are living into old age and are more likely to die from smoking, said Brad Hare, director of HIV care and prevention at Kaiser Permanente San Francisco.
Researchers are working toward a cure and people without HIV can take a prevention pill to keep them from becoming infected. Continue reading →
Kris Hickman (@the_index_case) is a graduate research assistant for AHCJ, pursuing a master’s degree in public health. She has a bachelor's degree in anthropology, with a minor in journalism, from the University of Missouri. She spent two years in Zambia as an HIV/AIDS community education volunteer in the Peace Corps. She aspires to be an epidemiologist and science writer.
Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.
A report released Friday by the Office of the Inspector General found that, under the Part D program, Medicare paid for HIV drugs for 150 dead recipients.
An analysis of Prescription Drug Event (PDE) records for HIV drugs in 2012 determined that CMS’s current practices allowed most of these payments to occur. Although CMS has processes in place that reject PDE records for drugs with dates of service more than 32 days after death, in some cases, claims that fell outside this window were paid. Most of these drugs were dispensed by retail pharmacies.
According to OIG, “Drugs that treat the human immunodeficiency virus (HIV) can be a target for fraud, waste, and abuse, primarily because they can be very expensive.” The report points out, for example, that one common antiretroviral drug costs approximately $1,700 per month. HIV drugs accounted for one-quarter of one percent of all Part D drugs in 2012.